BridgeMD
New treatment option for Shingles
Official title Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
ClinicalTrials.gov ID: NCT05554068
What this study is testing
What is Shingrix?
Shingrix is an investigational medicine, being studied as a potential treatment for shingles.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Age ≥18 years
- ≥ 12 months and ≤ 36 months post-AlloSCT
- Donor sources: matched related, matched unrelated, cord blood
- Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic...
- Any conditioning regimen
You likely can't join if
- Patients who had zoster after an allogeneic transplant and prior to enrollment
- Patients who are currently pregnant
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or...
- Patients who have had a relapse of their primary hematological disease
- Previous allogeneic stem cell transplantation
- Acute disease at the time of vaccination
See the full eligibility criteria
- Age ≥18 years
- ≥ 12 months and ≤ 36 months post-AlloSCT
- Donor sources: matched related, matched unrelated, cord blood
- Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and...
- Any conditioning regimen
- Any planned immunosuppressive prophylactic regimen
- Patients with chronic graft-versus-host disease on stable immunosuppression
- Ability to understand and the willingness to sign a written informed consent.
- Negative pregnancy test in female patients of childbearing potential
- Patients who had zoster after an allogeneic transplant and prior to enrollment
- Patients who are currently pregnant
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or other agents used in study.
- Patients who have had a relapse of their primary hematological disease
- Previous allogeneic stem cell transplantation
- Acute disease at the time of vaccination
- Thrombocytopenia that in the judgment of the investigator would make intramuscular injection unsafe.
The study team makes the final eligibility decision.
Where it's taking place
- Maywood, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Maywood, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.